ClinicalTrials.Veeva

Menu

Performance of Different Application Regimens of ACTINICA® on Protection From UVR-induced Erythema After One Day of Sun Exposure in Fair-skinned Healthy Subjects.

Galderma logo

Galderma

Status

Completed

Conditions

Healthy Subjects, Male or Female, of 18-60 Years Old, With Phototype I, II or III, Not Pre-treated/Pre-protected Skin

Treatments

Device: Actinica, 0.8 mg/cm2, 2 applications
Device: Actinica, 0.8 mg/cm2, 1 application
Device: Actinica, 2 mg/cm2, 1 application
Device: Actinica, 2 mg/cm2, 2 applications

Study type

Interventional

Funder types

Industry

Identifiers

NCT02251756
ID RCB: 2014-A00491-46 (Other Identifier)
RD.03.CIP.29114

Details and patient eligibility

About

Study objective To assess the performance of different application regimens of Actinica® on protection from UV rays-induced erythema throughout 1 day of sun exposure in fair-skinned healthy subjects (phototype I to III).

Study centers A total of 20 subjects will be enrolled in 1 site in France.

Methodology This will be a monocentre, randomised, controlled, investigator-blind, intra-individual comparative clinical investigation.

There will be a total of 6 visits for each subject. Each subject will participate for a period of maximum 35 days.

Study population Healthy subjects, male or female, at least 18-60 years old, with phototype I, II or III, not pre-treated/pre-protected skin, meeting specific inclusion/exclusion criteria.

The clinical investigation will be conducted in 2 parts.

Part 1 - SPF determination:

To determine the SPF of Actinica® with application of two different amounts (0.8 and 2 mg/cm2).

Part 2 - Sun exposure:

To assess the performance of the different application regimens of Actinica® on protection from UVR-induced erythema throughout 1 day of sun exposure.

Enrollment

20 patients

Sex

All

Ages

18 to 60 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Male or female, 18-60 years of age,
  2. Subject with Phototype I, II or III,
  3. Subject with individual typology angle (ITA) 28-70°,
  4. Subject with healthy skin / not tanned on the back,

Exclusion criteria

  1. Subject with obvious skin cancer forms within the test areas, 2. Subject with hairs on the treated area that might interfere with clinical investigation assessments, 3. Subjects who have performed sun bathing at least four months before enrolment, 10. History of sun allergy / Mallorca acne, active photo induced or photo aggravated disease, or abnormal response to the sun (e.g., photosensitive dermatoses, polymorphic light eruption, solar urticaria, systemic lupus erythematosus, or dermatomyositis).

  2. The subject has received, applied or taken the forbidden treatments within the specified time frame prior to the Day 0 visit (list available on request)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

20 participants in 4 patient groups

Actinica, 0.8 mg/cm2, 1application
Experimental group
Description:
Actinica, 0.8 mg/cm2, 1application over one day of sun exposure
Treatment:
Device: Actinica, 0.8 mg/cm2, 1 application
Actinica, 0.8 mg/cm2, 2 applications
Experimental group
Description:
Actinica, 0.8 mg/cm2, 2 applications over one day of sun exposure
Treatment:
Device: Actinica, 0.8 mg/cm2, 2 applications
Actinica, 2 mg/cm2, 1 application
Experimental group
Description:
Actinica, 2 mg/cm2, 1 application over one day of sun exposure
Treatment:
Device: Actinica, 2 mg/cm2, 1 application
Actinica, 2 mg/cm2, 2 applications
Experimental group
Description:
Actinica, 2 mg/cm2, 1 application over one day of sun exposure
Treatment:
Device: Actinica, 2 mg/cm2, 2 applications

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems